Mirum Pharmaceuticals opened lower at $93.54, compared with its previous close of $94.61. In the last trading session, the stock traded between $92.13 and $95.06. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Mirum Pharmaceuticals is now worth
$ 584.66
Giving a profit of
$ 484.66 (484.66%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 12 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-1.30 (-1.37%)
Day High
$95.06
Day Low
$92.13
Day Open
$93.54
Prev Close
$94.61
Volume
2,95,060
1W Return
-3.88%
1M Return
8.40%
3M Return
-4.99%
6M Return
-12.11%
1Y Return
30.84%
Fundamentals
Market Cap ($ Mn)
6,092
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-8.84%
ROCE
-3.35%
EPS (TTM)
$-0.63
Investment Returns
1 Week
-3.88%
1 Month
8.40%
3 Months
-4.99%
6 Months
-12.11%
9 Months
-6.58%
Financials
Quarterly
All values in $ Mn
111.6
Mar 25
127.8
Jun 25
133.0
Sep 25
148.9
Dec 25
176.2
Jun 26
185.7
Sep 26
Updates
13Nov
Mirum Pharmaceuticals grants inducement stock options and RSUs to new hires
Granted 26,126 stock options and 34,386 RSUs to 17 new employees. Stock option exercise price set at $94.42 per share. Awards issued under Nasdaq Listing Rule 5635(c)(4). Options vest over four years; RSUs vest over three years.
Today
12Nov
Citigroup raises Mirum Pharmaceuticals price target to $194, keeps Buy
Citigroup maintains a Buy rating on Mirum Pharmaceuticals. Price target raised from $184 to $194. Analyst Yigal Nochomovitz issued the revised estimate.
Yesterday
5Nov
RBC Capital maintains $155 price target on Mirum Pharmaceuticals
RBC Capital reiterated an Outperform rating on Mirum Pharmaceuticals. Analyst Luca Issi maintained the price target at $155. No changes were made to the existing valuation estimates.
8 days ago
4Nov
HC Wainwright raises Mirum Pharmaceuticals price target to $202
HC Wainwright & Co. maintains a Buy rating on Mirum Pharmaceuticals. Price target raised from $200 to $202 by analyst Swayampakula Ramakanth.
8 days ago
4Nov
Cantor Fitzgerald raises Mirum Pharmaceuticals price target to $160
Cantor Fitzgerald maintains Overweight rating on Mirum Pharmaceuticals. Price target raised from $155 to $160. Analyst Josh Schimmer issued the update.
Net product sales rose 40% YoY to $186 million in Q3FY26. FY26 sales guidance raised to $715-$720 million, beating $698.093 million estimate. Livmarli contributed $133 million, driving majority of quarterly revenue. Cash position stands at ~$500 million after convertible note repurchases.
